Moderna (NASDAQ:MRNA) Announces Quarterly Earnings Results

Moderna (NASDAQ:MRNA) issued its quarterly earnings results on Thursday. The company reported ($3.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.59) by $0.52, Briefing.com reports. The company had revenue of $167.00 million during the quarter, compared to the consensus estimate of $93.26 million. Moderna had a negative net margin of 68.84% and a negative return on equity of 10.23%. Moderna’s revenue was down 91.0% on a year-over-year basis. During the same period in the prior year, the company earned $0.19 EPS.

Moderna Stock Down 0.5 %

Shares of NASDAQ:MRNA traded down $0.59 on Friday, reaching $125.00. The company had a trading volume of 4,512,362 shares, compared to its average volume of 4,144,759. The stock has a market capitalization of $47.86 billion, a P/E ratio of -10.07 and a beta of 1.57. The stock has a 50-day moving average price of $105.05 and a 200 day moving average price of $94.37. Moderna has a twelve month low of $62.55 and a twelve month high of $142.79. The company has a quick ratio of 3.36, a current ratio of 3.42 and a debt-to-equity ratio of 0.04.

Insider Activity at Moderna

In other Moderna news, CFO James M. Mock sold 647 shares of the company’s stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $61,186.79. Following the completion of the sale, the chief financial officer now owns 4,300 shares of the company’s stock, valued at $406,651. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Noubar Afeyan sold 15,000 shares of the business’s stock in a transaction on Wednesday, March 13th. The shares were sold at an average price of $108.54, for a total transaction of $1,628,100.00. Following the transaction, the director now owns 2,131,931 shares of the company’s stock, valued at $231,399,790.74. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO James M. Mock sold 647 shares of the stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total transaction of $61,186.79. Following the completion of the sale, the chief financial officer now directly owns 4,300 shares of the company’s stock, valued at $406,651. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 139,954 shares of company stock valued at $14,822,576. Corporate insiders own 15.70% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Canaccord Genuity Group increased their target price on shares of Moderna from $91.00 to $106.00 and gave the company a “hold” rating in a research note on Friday. Jefferies Financial Group reissued a “buy” rating and set a $125.00 price objective on shares of Moderna in a research note on Tuesday, April 9th. William Blair reaffirmed a “market perform” rating on shares of Moderna in a report on Monday, April 1st. Needham & Company LLC reissued a “hold” rating on shares of Moderna in a research note on Thursday. Finally, Oppenheimer upped their price objective on shares of Moderna from $142.00 to $163.00 and gave the company an “outperform” rating in a research note on Friday. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $129.55.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.